Rapid cloning of novel rhesus adenoviral vaccine vectors

Peter Abbink, Marinela Kirilova, Michael Boyd, Noe Mercado, Zhenfeng Li, Ramya Nityanandam, Ovini Nanayakkara, Rebecca Peterson, Rafael A. Larocca, Malika Aid, Lawrence Tartaglia, Tinaye Mutetwa, Eryn Blass, David Jetton, Lori F. Maxfield, Erica N. Borducchi, Alexander Badamchi-Zadeh, Scott Handley, Guoyan Zhao, Herbert W. VirginMenzo J. Havenga, Dan H. Barouch

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Human and chimpanzee adenovirus vectors are being developed to circumvent preexisting antibodies against common adenovirus vectors such as Ad5. However, baseline immunity to these vectors still exists in human populations. Traditional cloning of new adenovirus vaccine vectors is a long and cumbersome process that takes 2 months or more and that requires rare unique restriction enzyme sites. Here we describe a novel, restriction enzyme-independent method for rapid cloning of new adenovirus vaccine vectors that reduces the total cloning procedure to 1 week. We developed 14 novel adenovirus vectors from rhesus monkeys that can be grown to high titers and that are immunogenic in mice. All vectors grouped with the unusual adenovirus species G and show extremely low seroprevalence in humans. Rapid cloning of novel adenovirus vectors is a promising approach for the development of new vector platforms. Rhesus adenovirus vectors may prove useful for clinical development.

Original languageEnglish
Article numbere01924-17
JournalJournal of virology
Issue number6
StatePublished - Mar 1 2018


  • Adenoviruses
  • Live vector vaccines
  • Rhesus monkey
  • Vaccines


Dive into the research topics of 'Rapid cloning of novel rhesus adenoviral vaccine vectors'. Together they form a unique fingerprint.

Cite this